This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

. 1996 Sep;10(3):205-9.

doi: 10.2165/00019053-199610030-00002.

Interferon-alpha in hepatitis C. Dosage, costs and benefits

A Briggs¹, A Shiell

Affiliations

PMID: 10163569
DOI: 10.2165/00019053-199610030-00002

Interferon-alpha in hepatitis C. Dosage, costs and benefits

A Briggs et al. Pharmacoeconomics. 1996 Sep.

. 1996 Sep;10(3):205-9.

doi: 10.2165/00019053-199610030-00002.

Authors

A Briggs¹, A Shiell

Affiliation

¹ Centre for Socio-Legal Studies, University of Oxford, England.

PMID: 10163569
DOI: 10.2165/00019053-199610030-00002

No abstract available

PubMed Disclaimer

Comment in

Interferon-alpha in hepatitis C.
Koff RS. Koff RS. Pharmacoeconomics. 1997 May;11(5):491-2. doi: 10.2165/00019053-199711050-00010. Pharmacoeconomics. 1997. PMID: 10168036 No abstract available.

Similar articles

Cost effectiveness of interferon in chronic active hepatitis C.
Turnbull C, Sugano D. Turnbull C, et al. Med J Aust. 1994 Jul 18;161(2):169; author reply 170. Med J Aust. 1994. PMID: 8028544 No abstract available.
Cost effectiveness of interferon in chronic active hepatitis C.
Sallie R. Sallie R. Med J Aust. 1994 Jul 18;161(2):169-70. Med J Aust. 1994. PMID: 8080533 No abstract available.
Treatment of chronic type B and C hepatitis with interferon alfa: an economic appraisal.
Dusheiko GM, Roberts JA. Dusheiko GM, et al. Hepatology. 1995 Dec;22(6):1863-73. Hepatology. 1995. PMID: 7489999
The economics of hepatitis C virus.
Shah BB, Wong JB. Shah BB, et al. Clin Liver Dis. 2006 Nov;10(4):717-34. doi: 10.1016/j.cld.2006.08.026. Clin Liver Dis. 2006. PMID: 17164114 Review.
[Medico-economic assessment of the therapeutic management of patients with hepatitis C].
Loubière S, Rotily M, Moatti JP. Loubière S, et al. Gastroenterol Clin Biol. 2000 Nov;24(11):1047-51. Gastroenterol Clin Biol. 2000. PMID: 11139674 Review. French.

See all similar articles

Cited by

Assessment of viral genotype impact to the cost-effectiveness and overall costs of care for PEG-interferon-2α + ribavirine treated chronic hepatitis C patients.
Jakovljevic M, Mijailovic Z, Jovicic BP, Canovic P, Gajovic O, Jovanovic M, Petrovic D, Milovanovic O, Djordjevic N. Jakovljevic M, et al. Hepat Mon. 2013 Jun 19;13(6):e6750. doi: 10.5812/hepatmon.6750. eCollection 2013. Hepat Mon. 2013. PMID: 24032044 Free PMC article.
Interferon-alpha in hepatitis C.
Koff RS. Koff RS. Pharmacoeconomics. 1997 May;11(5):491-2. doi: 10.2165/00019053-199711050-00010. Pharmacoeconomics. 1997. PMID: 10168036 No abstract available.

References

1. J Hepatol. 1990;11 Suppl 1:S11-8 - PubMed
1. Semin Liver Dis. 1995 Feb;15(1):92-100 - PubMed
1. Semin Liver Dis. 1995 Feb;15(1):82-91 - PubMed
1. N Engl J Med. 1995 Jun 1;332(22):1463-6 - PubMed
1. N Engl J Med. 1989 Nov 30;321(22):1501-6 - PubMed

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
Medical
- MedlinePlus Health Information